Navigation Links
Test could predict which idiopathic pulmonary fibrosis patients will become severely ill
Date:2/3/2010

PITTSBURGH, Feb. 3 A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine. Their findings, published online last week in PLoS One, indicate that the body's immune cells attack healthy lung tissue, suggesting that IPF is in fact an immunologic disease.

In IPF, lung tissue gets progressively scarred, making it hard for patients to breathe, explained Steven R. Duncan, M.D., an associate professor in the Division of Pulmonary, Allergy and Critical Care Medicine at Pitt. The prognosis is grim; median survival is three years after diagnosis.

"If we knew who was in the gravest danger from this illness, we could direct them to lung transplantation or experimental therapy immediately," he said. "Also, we could possibly avoid prescribing grueling treatments for people whose disease is fairly stable."

Dr. Duncan and his colleagues may have found a way to test for that information. For their study, they collected blood samples from 89 IPF patients at various stages of disease severity, as well as 32 healthy individuals for comparison, and examined certain immune cells called CD4 T-cells. The cells, which typically respond to infectious threats, normally carry a surface protein called CD28.

The CD4 T-cells still bore their CD28 markers among patients whose disease was relatively stable. But, as a patient's disease got worse, the CD4 T-cells lost their CD28 protein markers and the cells were unusually "revved up," as Dr. Duncan put it. The greater the proportion of these distinctly abnormal cells in the blood, the greater the likelihood that the patient would quickly become gravely ill. In the study group, these patients were the ones who were most likely to require a lung transplant or to die within 1
'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. New adhesive device could let humans walk on walls
2. Epigenetics could help researchers determine any risks associated with low-dose radiation
3. Hospital scanner could curb nuclear waste threat
4. Research breakthrough could lead to new treatment for malaria
5. Energy-harvesting rubber sheets could power pacemakers, mobile phones
6. UCF professors vaccine could be lethal weapon against malaria, cholera
7. Genes found linked to breast cancer drug resistance could guide future treatment choices
8. Discovery of algaes toxic hunting habits could help curb fish kills
9. Even small dietary reductions in salt could mean fewer heart attacks, strokes and deaths
10. Blood test for schizophrenia could be ready this year
11. Ongoing human evolution could explain recent rise in certain disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... The National Science Foundation (NSF) recently awarded $55.5 ... Engineering Research Centers (ERCs) that will advance interdisciplinary ... Over the next five years, these Nanosystems ... innovations that address significant societal issues, such as ...
... more severe in the Southwest, trees are increasingly up ... middle elevations, University of Arizona researchers report in a ... of Geophysical Research Biogeosciences ., Lead author Jeremy Weiss, ... geosciences, said: "We know the climate in the Southwest ...
... human liver-chimeric mouse model developed at Oregon Health & Science ... at Seattle Biomedical Research Institute that will greatly accelerate studies ... The study findings are published online in the Journal ... in "Scientific Show Stoppers" on the JCI blog. ...
Cached Biology News:Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 3Droughts are pushing trees to the limit 2Droughts are pushing trees to the limit 3Droughts are pushing trees to the limit 4'Humanized' mice developed at OHSU enable malaria research breakthrough at Seattle BioMed 2'Humanized' mice developed at OHSU enable malaria research breakthrough at Seattle BioMed 3
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... , ... July 30, 2015 , ... As part of its 2015 growth plan and ... and technical service business units, Whitehouse Laboratories is pleased to announce that it ... to the Container Center of Excellence and will be strictly dedicated to basic USP 51, ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... of Finding a Cure for Laminitis, NEW ... the National,Thoroughbred Racing Association (NTRA) have joined forces ... - Barbaro Memorial Fund. The,partnership,s aim is to ... and encourage further support of cutting edge research ...
... NEW YORK, Jan. 31 American Oriental,Bioengineering Inc. ... distributor of,plant-based pharmaceutical and nutraceutical products, today announced ... Pharmaceutical,Biotechnology and Medical Device Conference at the Grand ... to meet with institutional,investors and to present at ...
... Md., Jan. 31 Martek Biosciences,Corporation (Nasdaq: MATK ... DHA researcher and expert Dr. Norman Salem, Jr., will ... president and chief,scientific officer., Dr. Salem is one ... of polyunsaturated fatty acids and lipids. He comes to ...
Cached Biology Technology:Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund 2Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer 2Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer 3
Harmful, Irritant, Combustible ,DEPC...
Permeabilization Solution, 5X...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: